Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 16/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 16/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322607 | 1.00 | RXRA (0.40) | RXRAGRIN1GRIN2BHRH3PSMD14 | |
| SCHEMBL6324373 | 0.81 | CYP1A2 (0.39) | HRH3USP2SIGMAR1 | |
| SCHEMBL6324377 | 0.81 | CYP1A2 (0.39) | HRH3USP2SIGMAR1 | |
| SCHEMBL6327797 | 0.77 | FEN1 (0.36) | RXRAGRIN1GRIN2B | |
| SCHEMBL6322205 | 0.75 | HRH3 (0.37) | HRH3PSMD14USP2MMP2SIGMAR1 | |
| SCHEMBL6322196 | 0.75 | HRH3 (0.37) | HRH3PSMD14USP2MMP2SIGMAR1 | |
| SCHEMBL6330742 | 0.72 | HPGD (0.39) | SIGMAR1 | |
| SCHEMBL6329235 | 0.71 | GAA (0.49) | SIGMAR1 | |
| SCHEMBL6329232 | 0.71 | GAA (0.49) | SIGMAR1 | |
| SCHEMBL5785899 | 0.71 | HRH3 (0.74) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | claimed |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | HRH3, HRH4, HRH1 | RXRA 1945/4885GRIN1 216/4885GRIN2B 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.